
MDXG
MiMedx Group Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.790
Open
6.710
VWAP
--
Vol
1.38M
Mkt Cap
963.02M
Low
6.465
Amount
--
EV/EBITDA(TTM)
16.68
Total Shares
147.60M
EV
897.40M
EV/OCF(TTM)
13.70
P/S(TTM)
2.82
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
102.56M
+10.39%
--
--
93.32M
+11.02%
--
--
90.79M
+4.11%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for MiMedx Group, Inc. (MDXG) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -5.23%.
Revenue Estimates for FY2025
Revise Upward

+0.21%
In Past 3 Month
Stock Price
Go Down

-5.23%
In Past 3 Month
5 Analyst Rating

80.21% Upside
Wall Street analysts forecast MDXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXG is 11.75 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy

80.21% Upside
Current: 6.520

Low
11.00
Averages
11.75
High
12.00

80.21% Upside
Current: 6.520

Low
11.00
Averages
11.75
High
12.00
BTIG
maintain
2025-07-15
Reason
BTIG
Price Target
2025-07-15
maintain
Reason
BTIG believes the selloff in shares of Organogenesis (ORGO) on the Centers for Medicare and Medicaid Services' proposed 2026 physician fee schedule "may be incorrect." Advanced wound care is likely the biggest news out of proposal as Medicare made a point to highlight how much costs have risen over the past few years, the analyst tells investors in a research note. BTIG believes that given the starting rate of $125.38, it expects to see significant pricing upside and downside for products under the proposed payment structure based on their reported average selling prices relative to the proposed rate. In Q4 of 2024, Organogenesis' Apligraf had an average selling price of $30.57, the analyst tells investors in a research note. If the starting rate is finalized, the product would see a 310.1% increase in price, notes BTIG. On the other hand, the firm says MiMedx's (MDXG) EpiFix and EpiCord will drop lose 21% and 49%, respectively, based on their Q4 prices. BTIG views last night's share selloff as "draconian," believing the CMS proposal may bring consolidation and a clean-up of the market. It keeps a Buy rating on Organogenesis. The stock in premarket trading is down 17% to $3.73.
Northland
Outperform
maintain
$12
2025-06-19
Reason
Northland
Price Target
$12
2025-06-19
maintain
Outperform
Reason
Northland attributes year-to-date weakness in MiMedx shares to concerns around CMS reimbursement in the private physician setting that represents about 25% of revenue and technical pressure following breaks below the 50- and 200-day moving averages. However, the firm argues that the "dislocation is unsupported" and views the recent pullback as one that "presents a compelling entry point for long-term investors." The firm maintains an Outperform rating and $12 price target on the shares.
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$13
2025-02-27
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$13
2025-02-27
Reiterates
Buy
Reason
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$14 → $12
2024-08-01
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$14 → $12
2024-08-01
Maintains
Strong Buy
Reason
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$11
2024-08-01
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$11
2024-08-01
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for MiMedx Group Inc (MDXG.O) is 27.16, compared to its 5-year average forward P/E of 4.07. For a more detailed relative valuation and DCF analysis to assess MiMedx Group Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
4.07
Current PE
27.16
Overvalued PE
37.00
Undervalued PE
-28.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
9.00
Current EV/EBITDA
11.61
Overvalued EV/EBITDA
45.29
Undervalued EV/EBITDA
-27.30
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
2.74
Current PS
2.61
Overvalued PS
3.81
Undervalued PS
1.67
Financials
Annual
Quarterly
FY2025Q1
YoY :
+4.13%
88.21M
Total Revenue
FY2025Q1
YoY :
-39.17%
8.25M
Operating Profit
FY2025Q1
YoY :
-22.49%
7.02M
Net Income after Tax
FY2025Q1
YoY :
-16.67%
0.05
EPS - Diluted
FY2025Q1
YoY :
+1.22%
4.89M
Free Cash Flow
FY2025Q1
YoY :
-3.94%
81.12
Gross Profit Margin - %
FY2025Q1
YoY :
+79.35%
18.33
FCF Margin - %
FY2025Q1
YoY :
-25.61%
7.96
Net Margin - %
FY2025Q1
20.95
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.1M
USD
4
6-9
Months
526.3K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
1
1.3M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
8.1K
Volume
1
6-9
Months
76.3K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
6.7M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.1M
USD
4
6-9
Months
526.3K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
1
1.3M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MDXG News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
16:06:02
New
MiMedx sees FY25 revenue up low double-digits percent

2025-07-30
16:04:23
New
MiMedx reports Q2 EPS 6c, consensus 5c

2025-07-30
08:08:28
MiMedx announces strategic collaboration with Vaporox

Sign Up For More Events
Sign Up For More Events
News
8.0
07-28NASDAQ.COMNotable Monday Option Activity: MDXG, GRPN, GTES
4.0
07-15BenzingaCantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $11 Price Target
2.0
07-15BenzingaSimulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Sign Up For More News
People Also Watch

SCS
Steelcase Inc
10.330
USD
-1.71%

OXM
Oxford Industries Inc
38.790
USD
-6.93%

RBCAA
Republic Bancorp Inc
70.210
USD
-0.75%

KNSA
Kiniksa Pharmaceuticals International PLC
30.060
USD
-1.02%

AMC
AMC Entertainment Holdings Inc
2.910
USD
-1.69%

TPC
Tutor Perini Corp
47.650
USD
+1.58%

USPH
US Physical Therapy Inc
74.850
USD
-1.04%

SILA
Sila Realty Trust Inc
24.460
USD
-2.78%

TV
Grupo Televisa SAB
2.810
USD
+12.40%

SGML
Sigma Lithium Corp
5.510
USD
-7.94%
FAQ

What is MiMedx Group Inc (MDXG) stock price today?
The current price of MDXG is 6.52 USD — it has decreased -2.25 % in the last trading day.

What is MiMedx Group Inc (MDXG)'s business?

What is the price predicton of MDXG Stock?

What is MiMedx Group Inc (MDXG)'s revenue for the last quarter?

What is MiMedx Group Inc (MDXG)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for MiMedx Group Inc (MDXG)'s fundamentals?

How many employees does MiMedx Group Inc (MDXG). have?
